anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Starvation causes the accumulation of lipid droplets in the liver, a somewhat counterintuitive phenomenon that is nevertheless conserved from flies to humans. Much like fatty liver resulting from overfeeding, hepatic lipid accumulation (steatosis) during undernourishment can lead to lipotoxicity and atrophy of the liver. Here, we found that although surface populations of Astyanax mexicanus undergo this evolutionarily conserved response to starvation, the starvation-resistant cavefish larvae of the same species do not display an accumulation of lipid droplets upon starvation. Moreover, cavefish are resistant to liver atrophy during starvation, providing a unique system to explore strategies for liver protection. Using comparative transcriptomics between zebrafish, surface fish, and cavefish, we identified the fatty acid transporter slc27a2a/fatp2 to be correlated with the development of fatty liver. Pharmacological inhibition of slc27a2a in zebrafish rescues steatosis and atrophy of the liver upon starvation. Furthermore, down-regulation of FATP2 in Drosophila larvae inhibits the development of starvation-induced steatosis, suggesting the evolutionarily conserved importance of the gene in regulating fatty liver upon nutrition deprivation. Overall, our study identifies a conserved, druggable target to protect the liver from atrophy during starvation.
BACKGROUND: The nasopharynx serves as a crucial niche for the microbiome of the upper respiratory tract. However, the association between the intratumoral microbiota and host systemic inflammation and immune status in nasopharyngeal carcinoma (NPC) remain uncertain.
METHODS: We performed 5R 16S rDNA sequencing on NPC tissue samples, followed by diversity analysis, LEfSe differential analysis, and KEGG functional prediction. The analyses were based on indices such as AISI, SIRI, PAR, PLR, and NAR. Correlation analyses between microbes and these indices were performed to identify microbes associated with inflammation and immune status. Additionally, regression analysis based on tumor TNM stage was performed to identify key microbes linked to tumor progression. The head and neck squamous cell carcinoma (HNSC) transcriptome and the paired HNSC microbiome data from TCGA were utilized to validate the analyses.
RESULTS: The Proteobacteria, Actinobacteria, Firmicutes, and Bacteroidetes were the most enriched phyla in NPC tissues. Microbes within these phyla demonstrated high sensitivity to changes in host systemic inflammation and immune status. Proteobacteria and Firmicutes showed significant differences between inflammation groups. Actinobacteria varied specifically with platelet-related inflammatory indices, and Bacteroidetes genera exhibited significant differences between NAR groups. Corynebacterium and Brevundimonas significantly impacted the T stage of tumors, with a high load of Corynebacterium within tumors associated with a better prognosis CONCLUSION: Our analysis indicates that Proteobacteria play a crucial role in the inflammatory state of NPC, while Bacteroidetes are more sensitive to the tumor immune status.
Traditionally, RARP is performed using a trans-peritoneal technique that pass anteriorly to the bladder. This technique necessitates the dissection and/or manipulation of many structures, which might compromise post-operative urinary continence recovery. These structures include the pubo-prostatic ligament, Santorini plexus, neurovascular bundle, and veil of Aphrodite. Recently, a "Retzius-sparing" technique to perform RARP has beed described. This approach passes posteriorly to the bladder, through the space of Douglas, which should minimize the damaged to the aforementioned structure. Theoretically, the latter technique should improve post-operative urinary continence recovery. However, a randomized comparison between the "traditional" RARP and "Retzius-sparing" RARP is still lacking.
Immediately post operatively 24 hours compression therapy starts with "Elastomull Haft ®", an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts.
OBJECTIVE: The clinical manifestation of vertigo caused by vestibular neuritis is acute and persistent vertigo, accompanied by nausea, vomiting, and dizziness. Low-dose glucocorticoid therapy is recommended in the acute phase, while drug therapy is not recommended in the recovery phase. Therefore, it is of certain clinical value to explore other treatment options. This study hopes to better fill the current research gap in non-drug treatment of vertigo caused by vestibular neuritis.
METHODS: The medical data of 96 patients with vertigo caused by vestibular neuritis in our hospital from May 2019 to May 2021 were retrospectively analyzed. According to different treatment methods, they were divided into the control group (routine treatment regimen) and the experimental group (vestibular rehabilitation training combined with the medical wisdom platform), with 48 cases in each group, and the clinical efficacy of the two groups was compared.
RESULTS: The total effective rate of treatment was 95.83% in the experimental group, which was significantly higher than 79.17% in the control group (χ2 = 6.095, P = .014). In the two groups, the scores of dizziness handicap inventory (DHI) and vestibular symptom index (VSI) decreased. In contrast, the scores of Tinetti performance-oriented mobility assessment (POMA) and functional independence measure (FIM) increased after treatment. After treatment, the experimental group had significantly lower DHI score (t = 12.942, P < .001), distinctly higher POMA score (t = 9.940, P < .001), overtly lower VSI score (t = 8.783, P < .001), and notably higher FIM score than the control group (t = 12.649, P < .001).
CONCLUSION: The application of vestibular rehabilitation training combined with the medical wisdom platform is beneficial to patients with vertigo caused by vestibular neuritis, which provides reference for the subsequent treatment of this disease and has a certain clinical promotion value.
<P>PROBLEM TO BE SOLVED: To provide a method for promoting bone formation in an individual.  <P>SOLUTION: This method for identifying a compound useful for increasing a bone mass in the individual by using a GPR119 receptor is provided. The agonists of the GPR119 receptor are useful as therapeutic agents for treating or preventing a state characterized by having a low bone mass such as that in osteoporosis and increasing the bone mass in the individual. The agonists of the GPR119 promote the bone formation in the individual. In a certain enbodiment, the individual is a human.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention belongs to the field of healthy drinks and in particular relates to a traditional medicinal composition used for preparing health care wine, health care wine prepared from the traditional medicinal composition and a preparation method of the traditional medicinal composition. The traditional medicinal composition used for preparing the health care wine comprises 10-150 parts of cistanche, 10-50 parts of American ginseng, 10-50 parts of medlar, 10-50 parts of sealwort and 1-5 parts of safflower. The health care wine is prepared from white wine with alcoholic strength of 38-65%vol and any one traditional medicinal composition in weight ratio of (6-40):1. The health care wine provided by the invention adopts multiple traditional Chinese medicines which are compatible and coordinated each other, take the advantages of each other and are safe and efficient, good taste and safety of a health care wine product is guaranteed, bitter and astringent smell of medicine is removed, and even a person not used to drinking can accept the health care wine. The modern pharmacological experiments prompt that the traditional medicinal composition used for preparing the health care wine has the function of relieving physical fatigue. By adopting the traditional medicinal composition used for preparing the health care wine, content of active ingredients in the health care wine product can be obviously increased, and production efficiency is greatly improved, so that the traditional medicinal composition used for preparing the health care wine has a good industrial application prospect.
The invention discloses a Lactobacillus, paracasei subsp. paracasei strain, a bacteriostatic composition and applications thereof. The preservation number of the SG96 strain microorganism is CGMCC2697. The strain can inhibit the growth of pathogenic bacteria of Escherichia coli, Salmonella typhimurium and the like, and has bacteria killing effect. The invention also discloses a bacteriostatic composition containing the Lactobacillus, paracasei subsp. paracasei strain SG96. The composition can be prepared into animal water-feeding additives, animal fodder additives, animal and human medical compositions, food additives, beverage additives, foods, beverages, health foods, and the like.
1-Aminoalkylcycloalkyl cpds. as bactericides fungicides disinfectants, insecticides and acaricides New cpds. of formula (where R0 is 10-14 ring C cycloalkylidene R1 is acyl; alk is lower alkylene seps. R0 from R2 by 3C atoms or gp. of formula -C(=CH2)-CH2-, and R2 is tert. amine) and their salts may be prepd by acylating the corresp. cpds where R1 is H, and opt. converting to required optical isomer or salt. The 1-aminoalkylcycloalkanols have bactericidal and fungicidal action, esp. against dematophytes, in human and veterinary medicine, the acyl cpds. are useful as disinfectants, and both show insecticidal, acaricidal and fungicidal action.
Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
Phase 2: 40 (20 each in treatment and control group). The Study Product is CytoSorb. Patients included will receive a CytoSorb filter. The device has a CE-mark and is used in accordance with its CE-Certification. Patients are installed as early as possible after exclusion of the bleeding source and are treated with the CytoSorb Adsorber for 48 hours. Blood flow will be set at least 200 ml/min.
Participants who allocate to the control group will only receive information to thank them and encourage them to complete the study. They will receive "STOP touching your face" program after the end of this study. The repeat measurement of the face-touching behavior will be in at least 1-hour interval.
The present invention relates to a composition for preventing and treating xerostama, containing a compound isolated from an Ixeris dentata (Thunb.) Nakai. extract as an active ingredient. According to the present invention, the Ixeris dentata (Thunb.) Nakai. extract promotes amylase secretion when co-treating high-concentration glucose and Ixeris dentata (Thunb.) Nakai. together, in an experiment using human salivary gland (HSG) cells. In addition, the extract decreases the expression of proteins associated with endoplasmic reticulum stress, and an oxidation-reduction environment in an endoplasmic reticulum associated with the protein synthesis is well maintained after short-term and long-term co-treatment of high-concentration glucose. Thus, the composition of the present invention can be useful as a pharmaceutical composition for preventing and treating xerostama and a functional health food as well.
Various embodiments automatically generate a patient presence for a patient portal. In one embodiment, a secure communication is received from at least one electronic health management system. The secure communication comprises at least patient identifying information associated with a given individual. A set of user profiles associated with the patient portal is analyzed based on the patient identifying information. A determination is made, based on the analyzing, that the given individual fails to include an account with the patient portal. The given individual is automatically registered with the patient portal based on the determination. A communication is automatically sent to at least one of the electronic health management system and the given individual, and includes at least the login identifier, the password. The communication notifies the at least one of the electronic health management system and the given individual that the given individual has been automatically registered with the portal.
The invention relates to polysaccharide, in particular to application of natural homogeneous polysaccharide in longtube ground ivy herb in preparing anticomplement medicines and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The invention carries out active guide separation on the longhairy antenoron herb aqueous extract to obtain two homogeneous polysaccharides which are respectively named as GLP-1 and GLP-2. The structural characteristics of Glechoma longituba polysaccharide GLP-1 and Glechoma longituba polysaccharide GLP-2 are described as follows: (1) GLP-1 is heteropolysaccharide mainly composed of 5 monosaccharides, and is mainly connected in a galactose 1, 6-connected main chain, and other small amount of saccharides are connected on branched chains of the main chain. (2) GLP-2 is heteropolysaccharide mainly composed of 6 monosaccharides, the main connection mode is similar to GLP-1, the main chain is 1, 6-connection of galactose, and other small amount of sugar is connected on the branched chain of the main chain. In vitro hemolysis experiments prove that two Glechomae herba polysaccharide GLP-1 and GLP-2 have obvious inhibition on cell hemolysis caused by complement classical pathway activation, namely have obvious anticomplementary effect. CH (CH) 50 The values were 0.028. + -. 0.011 mg/mL and 0.056. + -. 0.015 mg/mL, respectively.
Heart failure presents a significant diagnostic and treatment problem. The mortality in the Czech Republic related to this condition is high. The current treatment strategy consists of the administration of medication to patients, in order to attenuate the clinical manifestations of the disease and to influence the overall survival of patients suffering from this condition. Another treatment option is a mini-invasive procedure, with implantation of a pacemaker with biventricular stimulation, or transplantation of the heart. Despite these treatment options, the mortality of patients due to heart failure remains high, and new approaches are being studied for the diagnostics and treatment of heart failure. Factors that may play an important role in earlier diagnostics are miRNA. These molecules are located in the circulating blood. They are being described as suitable prognostic markers of heart failure, which may contribute to earlier diagnostics and bring a better understanding of processes going on in the human body.

In the study, the authors will take blood samples in order to analyze the presence of miRNA. These levels of miRNA will be compared with heart ultrasound parameters of HF patients and healthy control subjects.
While CD4+ T cell depletion is key to disease progression in people living with HIV and SIV-infected macaques, the mechanisms underlying this depletion remain incompletely understood, with most cell death involving uninfected cells. In contrast, SIV infection of "natural" hosts such as sooty mangabeys does not cause CD4+ depletion and AIDS despite high-level viremia. Here, we report that the CARD8 inflammasome is activated immediately after HIV entry by the viral protease encapsulated in incoming virions. Sensing of HIV protease activity by CARD8 leads to rapid pyroptosis of quiescent cells without productive infection, while T cell activation abolishes CARD8 function and increases permissiveness to infection. In humanized mice reconstituted with CARD8-deficient cells, CD4+ depletion is delayed despite high viremia. Finally, we discovered loss-of-function mutations in CARD8 from "natural hosts," which may explain the peculiarly non-pathogenic nature of these infections. Our study suggests that CARD8 drives CD4+ T cell depletion during pathogenic HIV/SIV infections.
Diabetic kidney disease (DKD) is the most devastating complication of diabetes mellitus. Identification of patients at the early stages of progression may reduce the disease burden. The limitation of conventional markers such as serum creatinine and proteinuria intensify the need for novel biomarkers. The traditional paradigm of DKD pathogenesis has expanded to the activation of the immune system and inflammatory pathways. Monocyte chemo-attractant protein-1 (MCP-1) is extensively studied, as a key inflammatory mediator that modulates the development of DKD. Recent evidence supports the diagnostic role of MCP-1 in patients with or without proteinuria in DKD, as well as a significant role in the early prediction and risk stratification of DKD. In this review, we will summarize and update present evidence for MCP-1 for diagnostic ability and predicting the progression of DKD.
BACKGROUND: Posterior cortical atrophy (PCA) is a form of dementia that frequently displays significant visual dysfunction and relatively preserved cognitive and executive functions, thus hindering early diagnosis and treatment. This study aimed to investigate possible fundus markers in PCA patients and compare them with those of typical Alzheimer's disease (AD) patients to seek potential diagnostic patterns.
METHODS: Age-matched PCA and AD patients and healthy controls (HC) completed optometry, intraocular pressure measurement, neuropsychologic assessments, optical coherence tomography (OCT), and optical coherence tomography angiography (OCTA) examination in one visit. Overall, six outcomes of thicknesses of various retinal layers and seven outcomes of the retinal microvascular network were calculated. After adjusting for age, sex, and years of education, the OCT and OCTA results were analyzed using analysis of covariance and generalized linear models. Correlation analyses were performed using Spearman correlation, and ROC curves were plotted.
RESULTS: Twelve PCA patients, nineteen AD patients, and thirty HC, aged 45-80 years were included. Fifty HC, thirty AD, and twenty PCA eyes were available for foveal avascular zone (FAZ) area analysis; forty-nine HC, thirty-four AD, and eighteen PCA eyes were available for OCT and OCTA assessments. PCA patients had thinner retinal nerve fiber layer and ganglion cell layer + inner plexiform layer than HC in the 0-3 mm circle and 1-3 mm ring. Few structural differences were observed between the AD group and the other two groups. The flow area of the superficial capillary plexus and the intermediate capillary plexus was smaller in the PCA group than in the HC group in the 0-1 mm circle, 0-3 mm circle. MMSE performed better than any combination of optical parameters in identifying AD and PCA from HC (AUC = 1), while the combination of MoCA, retinal thickness and vascular density of ICP in the 1-3 mm ring, with flow area of ICP in the 0-1 mm circle showed the strongest ability to distinguish PCA from AD (AUC = 0.944).
CONCLUSIONS: PCA patients exhibited similar impairment patterns to AD patients in the fundus structure and microvascular network. OCTA may aid in the non-invasive detection of AD and PCA, but still remains to be substantiated.
PROBLEM TO BE SOLVED: To provide an oral osmotic pressure drug delivery system capable of overcoming a delivery fault in a drug that is highly water-soluble but has a problem with its release from an osmotic pressure dosage form.SOLUTION: There is provided an oral osmotic pressure drug delivery system that includes, when formulating by a standard osmotic pressure delivery system, a highly water-soluble drug showing an irregular or incomplete release profile and at least one release promoter. It is desirable that a water-solubility of the drug is at least 30 mg/ml. It is desirable that the drug is prostacyclin, especially treprostinil. It is desirable that the release promoter is selected from a group of wicking medicine, complexing agent, and micelle formation medicine. It is desirable that the wicking medicine is selected from a group including a surfactant and a non-swelling hydrophilic polymer. It is desirable that the non-swelling hydrophilic polymer is polyethylene glycol or the like, the complexing agent is polyvinylpyrrolidone or the like, and the micelle formation medicine is fatty acid sorbitan ester or the like.
The present invention is in the field of gene therapy, particularly targeted delivery of transgene-encoding constructs to the liver for expression of beneficial (therapeutic) proteins. In particular, the invention relates to the treatment of hemophilias such as Hemophilia A. The present invention describes compositions and methods for expressing a transgene in a liver cell. The transgene may be expressed extrachromosomally (episomally) or may be integrated into the genome of the liver cell. In some embodiments, the transgene encodes a protein involved in the clotting cascade. In preferred embodiments, the transgene encodes a FVIII polypeptide. Fig. 1
PROBLEM TO BE SOLVED: To prevent a side effect and to enable a patient to be accepted without an uncomfortable feel by incorporating a carrier containing a drug in a subsaturation state into a reservoir of a flow rate considerably greater than the drug skin flow rate when the drug is provided in a saturated state. SOLUTION: The drug is incorporated into the drug reservoir in the form of a simple matrix containing the subsaturation solution of the drug in the carrier or in the form of a fibrous body penetrated with the subsaturated solution of the drug into the carrier. The reservoir is provided with a means for maintaining the delivery relation between the skin and the drug. Further, the reservoir is provided with a lining for reservoir protection and/or for preventing the reverse diffusion of the drug, a structural layer for impartation of mechanical characteristics and/or a release lining layer to be removed before use. The drug solubility and size of the carrier are so selected that the subsaturation state of the reservoir may be maintained during a medication system to enable the provision of the necessary drug accumulation quantity.  As a result, a physiological level, diurnal rhythm and active metabolism may be achieved and maintained.
NEW MATERIAL:2-N-{3-[3-( 1-Piperidinomethyl )phenoxy]propyl}amino-5-amino- 1,3,4-thiadiazole. USE:It has excellent antagonistic activity to histamine H2 receptor, and is useful as an agent for suppressing the secretion of the gastric acid and as an antiulcer agent. it has long-acting activity and no side effect, and can be administered orally or parenterally. PREPARATION:The compound of formula I can be produced by the cyclization reaction of the compound of formula II. The reaction is carried out in an organic solvent such as benzene, toluene, etc. in the presence of a condensation agent such as N,N'-dicyclohexyl-carbodiimide, diethyl azodicarboxylate, and triphenyl phosphine, etc. at room temperature or under refluxing. The amount of the condensation agent is usually 1-3mol of N,N'-dicyclohexyl carbodiimide per 1mol of the compound of formula II.